- Home
- KPRX vs EVGN Comparison
KPRX vs EVGN Comparison
Compare KPRX & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- EVGN
- Stock Information
- Founded
- KPRX 1998
- EVGN 1999
- Country
- KPRX United States
- EVGN Israel
- Employees
- KPRX N/A
- EVGN N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- EVGN Agricultural Chemicals
- Sector
- KPRX Health Care
- EVGN Industrials
- Exchange
- KPRX Nasdaq
- EVGN Nasdaq
- Market Cap
- KPRX 9.2M
- EVGN 10.9M
- IPO Year
- KPRX N/A
- EVGN N/A
- Fundamental
- Price
- KPRX $2.15
- EVGN $1.21
- Analyst Decision
- KPRX Strong Buy
- EVGN Strong Buy
- Analyst Count
- KPRX 1
- EVGN 1
- Target Price
- KPRX $10.00
- EVGN $3.50
- AVG Volume (30 Days)
- KPRX 53.1K
- EVGN 54.1K
- Earning Date
- KPRX 11-07-2025
- EVGN 11-20-2025
- Dividend Yield
- KPRX N/A
- EVGN N/A
- EPS Growth
- KPRX N/A
- EVGN N/A
- EPS
- KPRX N/A
- EVGN N/A
- Revenue
- KPRX N/A
- EVGN $9,444,000.00
- Revenue This Year
- KPRX N/A
- EVGN N/A
- Revenue Next Year
- KPRX N/A
- EVGN $12.35
- P/E Ratio
- KPRX N/A
- EVGN N/A
- Revenue Growth
- KPRX N/A
- EVGN 42.25
- 52 Week Low
- KPRX $2.05
- EVGN $0.95
- 52 Week High
- KPRX $4.18
- EVGN $2.42
- Technical
- Relative Strength Index (RSI)
- KPRX 33.03
- EVGN 45.87
- Support Level
- KPRX $2.26
- EVGN $1.15
- Resistance Level
- KPRX $2.39
- EVGN $1.33
- Average True Range (ATR)
- KPRX 0.14
- EVGN 0.06
- MACD
- KPRX -0.02
- EVGN -0.00
- Stochastic Oscillator
- KPRX 16.03
- EVGN 35.71
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About EVGN Evogene Ltd
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.